Residual risk
In patients with chronic kidney disease and type 2 diabetes
Residual risk remains despite available treatments
Despite the available treatments, a residual risk of adverse clinical outcomes still exists in patients with chronic kidney disease and type 2 diabetes. Treatments aimed at inflammation and fibrosis pathways may help meet this unmet medical need
Residual risk of adverse clinical events in the CREDENCE study, despite treatment with a sodium-glucose co-transporter-2 inhibitor and an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker
CI, confidence interval; CV, cardiovascular; ESKD, end-stage kidney disease; HR, hazard ratio; SCr, serum creatinine
Perkovic V, et al. N Engl J Med 2019;380:2295–2306
MA-M_FIN-ALL-0200-1
